Stockpolly
Search
ALXO · NASDAQ · Biotechnology

ALX Oncology (ALXO)

Develops evorpacept and ALX2004 for clinical-stage cancer studies.

$2.01
Pre-market−0.07 (−3.37%)
At close$2.08(+5.05%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
534838413331322723231918
Research & development464232352624241817181413
866767855555
Selling & marketing000000000000
General & administrative866767855555
Other expenses000000030000
Operating income−53−48−38−42−33−31−32−27−23−23−19−18
232221110010
Interest income333322111112
Interest expense000000000000
Other non-operating income−3−3−3−3−2−2−1−1−1−1−10
Income before tax−51−45−36−39−31−29−31−26−22−23−18−18
Net income from continuing operations−51−45−36−39−31−29−31−26−22−23−18−18
Net income−51−45−36−39−31−29−31−26−22−23−18−18
EPS, basic−$1.24−$0.93−$0.71−$0.76−$0.58−$0.55−$0.58−$0.49−$0.41−$0.42−$0.17−$0.13
EPS, diluted−$1.24−$0.93−$0.71−$0.76−$0.58−$0.55−$0.58−$0.49−$0.41−$0.42−$0.17−$0.13
Weighted average shares, basic41495052535353535454105136
Weighted average shares, diluted41495052535353535454105136
EBITDA−50−45−35−39−30−29−30−25−22−22−17−18
Depreciation & amortization000000000000
EBIT−51−45−35−39−30−29−30−26−22−22−18−18